99mTc-annexin V-128

99mTc-annexin V-128 is an investigational radiopharmaceutical imaging agent developed for the non-invasive detection of apoptosis (programmed cell death) in vivo. It consists of a recombinant variant of human annexin V, known as annexin V-128, which has been engineered for optimal labeling with the radioisotope technetium-99m (99mTc). Annexin V has a high natural affinity for phosphatidylserine, a phospholipid that is normally sequestered on the inner leaflet of the cell membrane but is externalized during the early stages of apoptosis. By binding to these exposed phosphatidylserine residues, 99mTc-annexin V-128 serves as a molecular probe that can be visualized using Single Photon Emission Computed Tomography (SPECT) imaging. Columbia University is evaluating this agent in Phase 2 clinical trials to detect perioperative lung injury and destructive processes in patients undergoing major surgery, such as the Whipple procedure, particularly in those with Chronic Obstructive Pulmonary Disease (COPD).

Other names

technetium Tc 99m annexin V-128Annexin V-128 labeled with 99mTc